Hennion & Walsh Asset Management Inc. cut its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 33.8% during the ...

We recently compiled a list of the 15 Best Cheap Stocks to Buy for 2025. In this article, we are going to take a look at ...

Bristol Myers Squibb (BMY) ended the recent trading session at $56.29, demonstrating a -0.16% swing from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain ...

Jefferies has recently raised Bristol-Myers Squibb Co (BMY) stock to Buy rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the ...

Analysts at Leerink Partnrs boosted their Q4 2024 EPS estimates for Bristol-Myers Squibb in a report released on Sunday, ...

AbbVie will commit less capital towards experimental medicines for psychiatric disease, CEO Robert Michael said at an ...

Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $55.74 which represents a slight increase of $0.38 or 0.69% from the prior close of $55.36. The stock opened at $55.5 and ...

Analyst David Risinger of Leerink Partners reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target ...

This was the stock's third consecutive day of losses.

Bristol Myers Squibb CEO Christopher Boerner said $1.5B in annual cost savings should be achieved by the end of the year.

Bernstein analyst Courtney Breen maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) yesterday and set a price target of ...